 |
|
siplizumab
A monoclonal immunoglobulin G1 antibody with potential antineoplastic activity. Siplizumab binds to CD2, a specific receptor found in T cells and NK cells, thereby triggering a host immune response that results in lysis of CD2+ cells, selective suppression of the immune system, and control of activated T cell growth. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
| Synonym: | | anti-CD2 monoclonal antibody | | | | Code name: | | MEDI-507 | | |
|
|
